Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MICARDIS vs BENICAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Telmisartan is an angiotensin II receptor antagonist (ARB) that selectively and competitively blocks the binding of angiotensin II to the AT1 receptor, resulting in vasodilation, reduced aldosterone secretion, and decreased blood pressure.
Olmesartan medoxomil is a prodrug that is hydrolyzed to olmesartan, a selective angiotensin II receptor type 1 (AT1) antagonist. It blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II, reducing blood pressure.
Treatment of hypertension (FDA-approved),Cardiovascular risk reduction in patients unable to take ACE inhibitors (off-label)
Treatment of hypertension in adults and children ≥6 years,Off-label: Diabetic nephropathy, heart failure
40-80 mg orally once daily.
Initial: 20 mg orally once daily; titrate to 40 mg once daily. Maximum 40 mg/day.
Terminal elimination half-life is approximately 24 hours (range 20-30 hours), supporting once-daily dosing. Steady-state achieved in 5-7 days.
Terminal elimination half-life is approximately 13–15 hours after multiple dosing, supporting once-daily dosing.
Telmisartan is metabolized by glucuronidation via UGT1A3 and UGT2B7; minimal CYP450 metabolism.
Prodrug olmesartan medoxomil is rapidly hydrolyzed to active olmesartan by esterases in gastrointestinal tract. Olmesartan is not metabolized by CYP450 enzymes and is excreted unchanged in bile and urine.
Primarily biliary/fecal (approximately 60% as unchanged drug); renal elimination accounts for about 40% (mostly unchanged drug and inactive metabolites). Total recovery in feces: 60-70%; urine: 30-40%.
Olmesartan is excreted primarily in feces (approximately 50–65%) via biliary elimination, with about 35–50% eliminated renally in urine as unchanged drug.
Highly bound (>99.5%), primarily to albumin and α1-acid glycoprotein. Binding is saturable at high concentrations but clinically not significant at therapeutic doses.
Highly protein-bound (approximately 99%) to serum albumin.
Apparent volume of distribution: approximately 500 L (about 7 L/kg), indicating extensive extravascular distribution.
Volume of distribution is approximately 17 L (0.2–0.3 L/kg), indicating limited extravascular distribution.
Oral bioavailability is variable, approximately 40-60% (mean 50%) due to first-pass metabolism. Food reduces bioavailability by about 20%, but clinical effect is not significantly altered.
Oral bioavailability is about 26–29% (absolute).
No dose adjustment required for GFR ≥30 m L/min. Not studied in GFR <30 m L/min or dialysis; use caution.
No adjustment for GFR ≥30 m L/min. For GFR <30 m L/min, initial dose 20 mg once daily; maximum 40 mg/day.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), maximum dose is 40 mg once daily.
No adjustment for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended in severe impairment (Child-Pugh C).
Safety and efficacy not established in pediatric patients (<18 years).
Safety and efficacy not established for pediatric patients <18 years.
No specific dose adjustment needed; start at lower end of dosing range (40 mg) due to possible increased sensitivity.
Initial 20 mg once daily; caution due to potential for reduced renal function. Monitor BP and electrolytes.
No FDA boxed warning.
No FDA black box warning.
Fetal toxicity: Use in pregnancy can cause injury and death to the fetus; discontinue when pregnancy is detected.,Hypotension in volume- or salt-depleted patients,Renal function impairment: Monitor serum creatinine and potassium,Hyperkalemia: Risk increased with renal impairment, diabetes, or concomitant K+ supplements/sparing diuretics,Avoid coadministration with aliskiren in patients with diabetes
May cause fetal harm if used during pregnancy,Avoid use in patients with severe renal impairment (Cr Cl <20 m L/min),Sprue-like enteropathy (severe chronic diarrhea with weight loss),Hypotension in volume-depleted patients,Hyperkalemia,Renal function deterioration in patients with renal artery stenosis
Concomitant use with aliskiren in patients with diabetes mellitus,Known hypersensitivity to telmisartan or any component,Pregnancy (second and third trimesters)
Concomitant use with aliskiren in patients with diabetes mellitus,History of hypersensitivity to any component of the product
No specific food restrictions. Avoid salt substitutes containing potassium chloride. Maintain consistent dietary habits to avoid fluctuations in blood pressure. Grapefruit juice has no known interaction but other drugs may be affected; consult pharmacist for all medications.
No significant food interactions; may be taken with or without food. However, avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, spinach) if renal impairment is present or if taking potassium supplements.
Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal and neonatal morbidity and death when used during the second and third trimesters. First trimester exposure does not appear to increase the risk of congenital anomalies, but should be avoided due to potential unknown risks. Oligohydramnios, fetal renal dysfunction, skull hypoplasia, hypotension, and hyperkalemia are risks associated with second and third trimester exposure.
Pregnancy Category C (first trimester) and D (second and third trimesters). Exposure during the first trimester is associated with a potential risk of teratogenicity, though data are limited. Use in the second and third trimesters is known to cause fetal renal dysfunction, oligohydramnios, skull ossification deficits, and neonatal hypotension, hyperkalemia, and renal failure.
No data on the excretion of telmisartan into human milk are available. Telmisartan is excreted in the milk of lactating rats. Because of the potential for adverse effects in the nursing infant, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio is unknown.
Minimal excretion into breast milk; M/P ratio is unknown. The American Academy of Pediatrics considers use compatible with breastfeeding, but caution is advised in preterm infants or those with renal impairment.
No dose adjustment guidelines are available due to lack of pharmacokinetic studies in pregnancy. However, due to the risks associated with RAS inhibition, telmisartan should be discontinued as soon as pregnancy is detected, and alternative antihypertensive therapy should be initiated if needed.
No dose adjustment typically required in pregnancy, but pharmacokinetic changes (increased volume of distribution, altered renal clearance) may necessitate careful blood pressure monitoring and dose titration. Avoid use during second and third trimesters if possible.
Monitor renal function and serum potassium before and during therapy, especially in patients with renal impairment or on potassium-sparing diuretics. May cause a rise in serum creatinine; usually minor and reversible. Avoid use in patients with biliary obstructive disorders or severe hepatic impairment due to primarily biliary excretion. Can be used with or without food; consistency recommended to avoid variability in absorption. Combination with aliskiren is contraindicated in diabetes. Adjust dose in patients with hepatic impairment; initial dose 40 mg once daily.
BENICAR (olmesartan) is an angiotensin II receptor blocker (ARB) used primarily for hypertension. It demonstrates a dose-dependent antihypertensive effect with a once-daily dosing regimen. Monitor renal function and serum potassium, especially in patients with renal impairment or those on potassium-sparing diuretics. Avoid use in pregnancy (category D).
Take this medication exactly as prescribed, usually once daily, with or without food. Try to take it at the same time each day.,Do not stop taking this medicine without consulting your doctor, even if you feel well. High blood pressure often has no symptoms.,If you have a pregnancy potential, use effective contraception and notify your doctor immediately if you become pregnant. This drug can harm an unborn baby.,Avoid alcohol and use caution when driving or operating machinery until you know how this medicine affects you, as dizziness may occur.,Do not use salt substitutes containing potassium without your doctor's approval. This medication may increase your potassium levels.,Stay adequately hydrated, especially during exercise or in hot weather, to prevent low blood pressure. Dehydration may increase the risk of low blood pressure.,Report any signs of infection (fever, sore throat) or swelling of the face, lips, or tongue, which may indicate a serious allergic reaction.,Keep all appointments for blood pressure checks and lab work (kidney function and potassium levels).
Take exactly as prescribed, usually once daily with or without food.,It may take 2-4 weeks to see full blood pressure lowering effect.,Do not take if pregnant or planning pregnancy; use effective contraception.,Avoid salt substitutes containing potassium unless approved by your doctor.,Report symptoms of high potassium (muscle weakness, slow heartbeat) or low blood pressure (dizziness, fainting).,Stay hydrated but avoid excessive dehydration (e.g., from diarrhea or vomiting).,Do not abruptly stop this medication without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MICARDIS vs BENICAR, answered by our medical review team.
MICARDIS is a Angiotensin II Receptor Blocker that works by Telmisartan is an angiotensin II receptor antagonist (ARB) that selectively and competitively blocks the binding of angiotensin II to the AT1 receptor, resulting in vasodilation, reduced aldosterone secretion, and decreased blood pressure.. BENICAR is a Angiotensin II Receptor Blocker that works by Olmesartan medoxomil is a prodrug that is hydrolyzed to olmesartan, a selective angiotensin II receptor type 1 (AT1) antagonist. It blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II, reducing blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MICARDIS and BENICAR depend on the specific clinical indication. These are both Angiotensin II Receptor Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MICARDIS is: 40-80 mg orally once daily.. The standard adult dose of BENICAR is: Initial: 20 mg orally once daily; titrate to 40 mg once daily. Maximum 40 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MICARDIS and BENICAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MICARDIS is classified as Category C. Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal and neonatal morbidity and death when used during the second and third trimesters. First trimester expos. BENICAR is classified as Category C. Pregnancy Category C (first trimester) and D (second and third trimesters). Exposure during the first trimester is associated with a potential risk of teratogenicity, though data a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.